Terns Pharmaceuticals Inc [TERN] stock prices are saw in change for the day to $3.15 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TERN shares have gain 8.62% over the last week, with a monthly amount glided 16.24%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer started tracking the stock with Outperform rating on October 31, 2024, and set its price target to $82. On June 22, 2023, Mizuho initiated with a Buy rating and assigned a price target of $16 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $18 on June 07, 2023. ROTH MKM initiated its recommendation with a Buy and recommended $23 as its price target on May 31, 2023. BMO Capital Markets started tracking with a Outperform rating for this stock on May 08, 2023, and assigned it a price target of $18. In a note dated February 14, 2023, JMP Securities initiated an Mkt Outperform rating and provided a target price of $17 on this stock.
The stock price of Terns Pharmaceuticals Inc [TERN] has been fluctuating between $1.87 and $11.40 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Terns Pharmaceuticals Inc [NASDAQ: TERN] shares were valued at $3.15 at the most recent close of the market. An investor can expect a potential return of 534.92% based on the average TERN price forecast.
Analyzing the TERN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.29 and Total Capital is -0.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Terns Pharmaceuticals Inc [NASDAQ:TERN]’s Current Ratio is 30.89. As well, the Quick Ratio is 30.89, while the Cash Ratio is 12.71.
Transactions by insiders
Recent insider trading involved Kuriakose Emil, Chief Medical Officer, that happened on Apr 01 ’25 when 952.0 shares were sold. Chief Business Officer, Jung Melita Sun completed a deal on Nov 30 ’24 to buy 2250.0 shares. Meanwhile, Chief Executive Officer Burroughs Amy L. bought 510.0 shares on Nov 30 ’24.
